Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Phast Corp. maintains a presence in the Biotechnology & Pharmaceuticals technology area, where it is currently managing 1 pending office action. This action constitutes the entirety of the company's active prosecution before the patent office. Such a focused portfolio suggests that the company may be prioritizing a specific innovation or is in a phase of limited filing activity, allowing for a concentrated effort on this particular application.
The examination of this portfolio is conducted by 1 distinct examiner and is situated within a distinct art unit. This concentration of resources means that the company's interactions with the patent office are highly localized. There is no need to coordinate between different art units, which can often lead to more consistent prosecution outcomes for the applicant and a clearer understanding of the examiner's technical expectations.
CLOW, LORI A is the busiest examiner for the portfolio, currently assigned the busiest examiner pending office action. Since the total number of pending actions is 1, CLOW, LORI A is the sole arbiter of the company's current patent applications. The progress of the portfolio is therefore entirely dependent on the resolution of the 1 pending office action under this examiner's review, making the upcoming response a critical milestone for the company's biotechnology interests.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLOW, LORI A | 1 | 64.2% | +28.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18446048 | ANALYZING AND USING MOTILITY KINEMATICS OF MICROORGANISMS | CLOW, LORI A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18446048 | ANALYZING AND USING MOTILITY KINEMATICS OF MICROORGANISMS | CLOW, LORI A | — |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18446048 | ANALYZING AND USING MOTILITY KINEMATICS OF MICROORGANISMS | CLOW, LORI A | 1687 | §101§102§103§112DP | Non-Final OA | — | Pending | Aug 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPhast Corp. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Lori A Clow has the most, with 1 of Phast Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.